Journal of Scleroderma and Related Disorders

Scope & Guideline

Leading the way in scleroderma and related disorder advancements.

Introduction

Immerse yourself in the scholarly insights of Journal of Scleroderma and Related Disorders with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2397-1983
PublisherSAGE PUBLICATIONS LTD
Support Open AccessNo
CountryItaly
TypeJournal
Convergefrom 2016 to 2024
AbbreviationJ SCLERODERMA RELAT / J. Scleroderma Relat. Disord.
Frequency3 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND

Aims and Scopes

The Journal of Scleroderma and Related Disorders focuses on advancing the understanding and management of systemic sclerosis and related conditions. It serves as a platform for innovative research that spans a wide array of clinical, epidemiological, and therapeutic aspects of scleroderma.
  1. Clinical Research on Systemic Sclerosis:
    The journal prioritizes original clinical studies that investigate various manifestations of systemic sclerosis, including its impact on organs such as the lungs, heart, and gastrointestinal tract.
  2. Therapeutic Approaches and Innovations:
    Research articles often explore novel therapeutic strategies and treatment protocols, including the use of biologics, immunosuppressants, and emerging therapies tailored to scleroderma.
  3. Patient-Centered Care and Quality of Life:
    The journal emphasizes studies that assess the quality of life and patient-reported outcomes for individuals with systemic sclerosis, highlighting the importance of psychosocial factors in disease management.
  4. Epidemiological and Public Health Studies:
    There is a consistent focus on epidemiological research that addresses the prevalence, risk factors, and long-term outcomes associated with systemic sclerosis across diverse populations.
  5. Interdisciplinary Approaches:
    The journal encourages interdisciplinary research that brings together insights from various fields such as rheumatology, dermatology, cardiology, and nutrition to provide a holistic understanding of systemic sclerosis.
Recent publications in the Journal of Scleroderma and Related Disorders indicate several emerging themes that reflect the evolving landscape of research in systemic sclerosis. These trends highlight areas of growing interest and potential impact on clinical practice.
  1. Impact of COVID-19 on Systemic Sclerosis:
    An increasing number of studies address the implications of COVID-19 on the management and outcomes of patients with systemic sclerosis, emphasizing the need for adaptive care strategies during the pandemic.
  2. Nutrition and Lifestyle Interventions:
    There is a rising focus on the role of nutrition and lifestyle factors in the management of systemic sclerosis, exploring how these elements can influence disease progression and patient well-being.
  3. Digital Health and Telemedicine:
    Emerging research is examining the use of digital health technologies and telemedicine in the management of systemic sclerosis, particularly in enhancing patient access to care and improving monitoring.
  4. Mental Health and Psychosocial Factors:
    Studies increasingly explore the psychosocial dimensions of living with systemic sclerosis, including the effects of mental health on disease management and quality of life.
  5. Machine Learning and Diagnostic Innovations:
    There is a growing interest in the application of machine learning and other advanced technologies to improve the diagnosis and management of systemic sclerosis, reflecting broader trends in healthcare innovation.

Declining or Waning

While the Journal of Scleroderma and Related Disorders continues to expand its focus, certain themes appear to be declining in prominence. This trend may reflect shifts in research priorities or advancements in understanding that have influenced the scope of inquiry.
  1. Rare and Uncommon Manifestations:
    Research focusing on rare manifestations of systemic sclerosis, such as specific types of skin involvement or rare comorbidities, has decreased. This may indicate a shift towards more prevalent and impactful aspects of the disease.
  2. Historical Perspectives and Case Reports:
    There has been a noticeable reduction in the publication of historical case reports and vignettes, suggesting a possible move towards more data-driven, clinical, and experimental research.
  3. Basic Science Research:
    The journal has seen a waning interest in basic science studies that do not directly translate to clinical implications, possibly due to a growing emphasis on translational research that bridges bench to bedside.

Similar Journals

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Pioneering Knowledge in Clinical Dermatology
Publisher: ADIS INT LTDISSN: 1175-0561Frequency: 6 issues/year

The American Journal of Clinical Dermatology, published by Adis International Ltd, is a leading peer-reviewed journal dedicated to advancing the field of dermatology. With a notable impact factor and a prestigious Q1 rank in both Dermatology and Miscellaneous Medicine categories, this journal stands out as a valuable resource for researchers and clinicians alike, offering cutting-edge insights into clinical practice and innovative treatment strategies. Its comprehensive scope encompasses a broad range of topics within dermatology, addressing both common and rare conditions, with a focus on emerging therapies and technologies. As it converges its publication years from 2000 to 2024, the journal remains an essential platform for disseminating high-quality research to professionals striving to improve patient care and outcomes. With the ISSN 1175-0561 and E-ISSN 1179-1888, the American Journal of Clinical Dermatology facilitates greater accessibility to pivotal findings within the field, making it an indispensable resource for anyone involved in dermatological research and practice.

Lupus Science & Medicine

Unlocking breakthroughs in lupus science and medicine.
Publisher: BMJ PUBLISHING GROUPISSN: 2053-8790Frequency: 1 issue/year

Lupus Science & Medicine is a leading open-access journal published by the BMJ Publishing Group, dedicated to advancing the understanding and treatment of lupus and related autoimmune diseases. Since its establishment in 2014, the journal has fostered an academic environment for researchers, healthcare professionals, and students, providing a platform for high-quality, evidence-based studies. With a notable impact in the fields of immunology and rheumatology, it currently holds a Q1 ranking in Rheumatology and Medicine (miscellaneous) and Q2 in Immunology, reflecting its significant contribution to these vital areas of medical research. The journal is indexed in Scopus, with a commendable rank in the 67th percentile for Rheumatology, making it a valuable resource for those seeking the latest insights into lupus management and treatment. The journal emphasizes the importance of open access, ensuring that research findings are widely available to enhance global knowledge and collaboration in the fight against lupus.

JOURNAL OF CLINICAL PERIODONTOLOGY

Shaping the Future of Oral Health Research
Publisher: WILEYISSN: 0303-6979Frequency: 12 issues/year

JOURNAL OF CLINICAL PERIODONTOLOGY, published by Wiley, is a leading academic journal dedicated to advancing the understanding and practice of periodontology. Since its inception in 1974, the journal has carved a niche in the field, achieving a remarkable Q1 ranking in Periodontics and securing a commendable Scopus rank of #2 out of 24 in Dentistry, placing it within the 93rd percentile of its category. With a robust commitment to publishing rigorous research, clinical studies, and comprehensive reviews, the journal provides an essential platform for researchers, dental professionals, and students to disseminate knowledge and keep abreast of the latest advancements in periodontal science. Although the journal is not open access, it remains highly influential in shaping the practices that underpin effective patient care and improving oral health globally. The journal's address in Hoboken, New Jersey, belies its international reach and the diverse contributions it attracts from around the world, ensuring its relevance and prestige in the rapidly evolving landscape of clinical periodontology.

Dermatology and Therapy

Unlocking the potential of dermatology through open access.
Publisher: ADIS INT LTDISSN: 2193-8210Frequency: 12 issues/year

Dermatology and Therapy is a prestigious Open Access journal, published by ADIS INT LTD since 2011, that has quickly established itself as a vital resource in the field of dermatology. With an impressive Q1 ranking in the Dermatology category as of 2023 and a commitment to disseminating high-quality research, this journal fosters innovation and knowledge exchange among professionals, researchers, and students alike. Its broad scope encompasses the latest advancements in dermatological therapies, contributing significantly to both clinical practice and academic research. Based in Germany and operating under a global perspective, Dermatology and Therapy provides an essential platform for open access research, encouraging unrestricted access to groundbreaking studies and fostering collaboration across borders. Join the community of dermatology experts by exploring the wealth of knowledge available in this influential journal.

JOURNAL OF RHEUMATOLOGY

Exploring the Complexities of Rheumatic Diseases
Publisher: J RHEUMATOL PUBL COISSN: 0315-162XFrequency: 12 issues/year

JOURNAL OF RHEUMATOLOGY, published by the J Rheumatol Publ Co, stands as a distinguished platform within the fields of rheumatology and immunology since its inception in 1974. With an impressive impact evidenced by its 2023 rankings—Q1 in Rheumatology and Q2 in both Immunology and Allergy—the journal has secured its position as a vital resource for researchers and practitioners alike. The journal is dedicated to advancing clinical and experimental knowledge in the pathogenesis, diagnosis, and management of rheumatic diseases, providing a rich repository of peer-reviewed articles that drive innovation in treatment protocols and patient care. Although it operates under a subscription model, the journal remains accessible to a broad audience committed to advancing their understanding of these critical areas. Located in Toronto, Canada, it continues to attract contributions from leading experts globally, making it an essential read for anyone keen on staying at the forefront of rheumatological research and practice.

Therapeutic Advances in Neurological Disorders

Connecting researchers and practitioners in the realm of neurology.
Publisher: SAGE PUBLICATIONS LTDISSN: 1756-2856Frequency: 1 issue/year

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Transforming skin health with every published study.
Publisher: MOSBY-ELSEVIERISSN: 0190-9622Frequency: 12 issues/year

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, published by Mosby-Elsevier, stands at the forefront of dermatological research and education. With an impressive impact factor and categorized as Q1 in Dermatology, this journal has established itself as a pivotal resource for healthcare professionals and researchers in the field. Since its inception in 1979, it has provided a platform for high-quality peer-reviewed articles, contributing significantly to advancements in dermatological science and practice through 2024. The journal commands an honorable position, ranking #8 out of 142 in the Scopus database's medicine dermatology category, placing it in the 94th percentile among its peers. Readers can access a wealth of cutting-edge studies, case reports, and reviews that address a broad spectrum of topics, from clinical dermatology to emerging therapies. In addition, the journal's commitment to excellence ensures it remains an essential tool for students, clinicians, and researchers dedicated to improving skin health and furthering knowledge in dermatology.

Multiple Sclerosis International

Empowering discoveries, enhancing treatments for multiple sclerosis.
Publisher: HINDAWI LTDISSN: 2090-2654Frequency:

Multiple Sclerosis International is a leading open-access journal dedicated to advancing the scientific understanding of multiple sclerosis (MS) and related neurological disorders. Published by HINDAWI LTD since 2010, this journal serves as a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality peer-reviewed articles that cover a diverse range of topics, including epidemiology, treatment strategies, and the latest advancements in MS research. With its commitment to open access, Multiple Sclerosis International ensures that critical findings are readily available to the global community, fostering collaborative efforts to improve patient outcomes and advance therapeutic approaches. The journal not only enhances scholarly discourse in the field but also significantly impacts clinical practices by presenting cutting-edge research and insights.

ANAIS BRASILEIROS DE DERMATOLOGIA

Empowering the Dermatology Community Through Research.
Publisher: ELSEVIER SCIENCE INCISSN: 0365-0596Frequency: 6 issues/year

ANAIS BRASILEIROS DE DERMATOLOGIA is a prestigious academic journal published by Elsevier Science Inc, specializing in the dynamic field of dermatology. With its Open Access model established in 2002, this journal ensures wide dissemination of research findings and facilitates collaboration within the dermatological community. Hailing from Brazil, it provides a platform for innovative research from both local and international contributors, spanning from its inception in 1963 to the current year, 2024. The journal positions itself as a vital resource in the dermatology sphere, currently ranked in the Q3 category for dermatology and holding a notable rank of 71 out of 142 in the Scopus rankings, placing it in the 50th percentile for its field. With a commitment to advancing knowledge and practice in dermatology, ANAIS BRASILEIROS DE DERMATOLOGIA is an essential read for researchers, professionals, and students eager to explore contemporary advancements and clinical practices.

Multiple Sclerosis Journal-Experimental Translational and Clinical

Advancing the Frontiers of Multiple Sclerosis Research
Publisher: SAGE PUBLICATIONS INCISSN: Frequency: 1 issue/year

Multiple Sclerosis Journal-Experimental Translational and Clinical, published by SAGE Publications, Inc., is an essential open-access platform since 2015 dedicated to advancing research in the field of multiple sclerosis and related neurological disorders. With an ISSN of N/A and an E-ISSN of 2055-2173, the journal aims to bridge the gap between experimental studies and clinical applications, offering valuable insights into cellular and molecular neuroscience as well as clinical neurology. The journal holds a reputable Q3 ranking in Cellular and Molecular Neuroscience and a Q2 ranking in Neurology (Clinical) for 2023, indicating its significant contribution to these fields. Positioned at the intersection of scientific discovery and clinical practice, the Multiple Sclerosis Journal serves as an indispensable resource for researchers, clinicians, and students dedicated to improving outcomes for individuals affected by multiple sclerosis and related disorders. With a Scopus ranking of #163/400 in Medicine - Neurology and #67/97 in Neuroscience, this journal continues to play a pivotal role in shaping the future of neurological research and therapy.